Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00681044 | HD Melphalan and SCT in Patients With IGDD or LCDD | terminated | Phase 2 | 5 | Boston Medical CenterOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00109889 | S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 24, 2017 | clinicaltrials |
| NCT00710151 |
| Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors |
| terminated |
| — |
| 80 |
| OHSU Knight Cancer InstituteOTHER |
| 2 |
| Apr 21, 2017 |
| clinicaltrials |
| NCT01750762 | Lenalidomide After Allo Transplant | terminated | Phase 1 | 1 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00645359 | Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma(dMRI) | terminated | — | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | terminated | Phase 2 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01534143 | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 1 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00490490 | Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy | terminated | Phase 2 | 8 | Stanford UniversityOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01207765 | Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma | terminated | Phase 2 | 8 | Tufts Medical CenterOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01484314 | Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00560352 | Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | terminated | Phase 1 | 16 | Bristol-Myers SquibbINDUSTRY | 4 | Mar 13, 2017 | clinicaltrials |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia(VISMOLY) | terminated | Phase 2 | 31 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT02473523 | Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia | terminated | N/A | 2 | St. Jude Children's Research HospitalOTHER | 1 | Mar 8, 2017 | clinicaltrials |
| NCT01878708 | A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma | terminated | Early Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01954784 | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma | terminated | Phase 1 | 8 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT02254551 | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | SCRI Development Innovations, LLCOTHER | 1 | Feb 16, 2017 | clinicaltrials |
| NCT01504490 | Phase I Study of CS-7017 and Bexarotene | terminated | Phase 1 | 9 | Georgetown UniversityOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT02113007 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma | terminated | Phase 2 | 2 | SCRI Development Innovations, LLCOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01389076 | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT02417129 | BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma | terminated | Phase 3 | 2 | Boehringer IngelheimINDUSTRY | 6 | Jan 30, 2017 | clinicaltrials |
| NCT00075608 | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | terminated | Phase 2 | 12 | Boston Medical CenterOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT01841021 | Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 | terminated | N/A | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2017 | clinicaltrials |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | terminated | Phase 2 | 5 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2017 | clinicaltrials |
| NCT01032148 | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | terminated | Phase 2 | 3 | Adam LernerOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01947309 | Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) | terminated | — | 176 | CelgeneINDUSTRY | 1 | Jan 12, 2017 | clinicaltrials |
| NCT02439138 | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | terminated | Phase 2 | 7 | University of RochesterOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT01555853 | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | terminated | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Dec 6, 2016 | clinicaltrials |
| NCT00978432 | Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | Phase 2 | 50 | Anne Beaven, MDOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT01745354 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | terminated | Phase 1 | 6 | Robert LowskyOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01609036 | An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma | terminated | — | 3 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01724294 | An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma | terminated | — | 113 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02020941 | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy | terminated | Phase 2 | 10 | Attaya SuvannasankhaOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01541072 | Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation(PALM2) | terminated | N/A | 34 | Centre Leon BerardOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | terminated | Phase 2 | 4 | Hoosier Cancer Research NetworkOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01144403 | A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. | terminated | Phase 2 | 8 | Hoffmann-La RocheINDUSTRY | 1 | Oct 18, 2016 | clinicaltrials |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | terminated | Phase 2 | 35 | Greg MonohanOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT00788606 | R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma | terminated | Phase 2 | 7 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT00912899 | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 12 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT01423760 | Common Safety Follow-up Trial of Tecemotide (L-BLP25) | terminated | N/A | 27 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 6, 2016 | clinicaltrials |
| NCT00278265 | Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia | terminated | Phase 2 | 12 | German CLL Study GroupOTHER | 1 | Oct 3, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | terminated | Phase 2 | 58 | Henrik GregersenOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Apr 28, 2017source: clinicaltrials